摘要
目的探讨埃索美拉唑三联疗法对十二指肠溃疡患者血清TNF-α及HMGB1表达的影响。方法选取2014年7月至2015年7月我院收治的100例十二指肠溃疡患者,按照随机数表法分为观察组和对照组。观察组采用埃索美拉唑三联疗法治疗,对照组采用奥美拉唑三联疗法治疗。观察两组患者治疗前后血清TNF-α、HM GB1、BAO及胃泌素水平的变化,比较治疗后的临床疗效及不良反应发生率。结果治疗后,观察组、对照组的TNF-α分别为(143.39±41.42)、(185.62±53.75)ng/L,HMGB1分别为(2.18±0.35)、(3.37±0.42)μg/L,BAO分别为(3.62±1.08)、(5.89±1.76)m Eq/h,胃泌素分别为(55.47±14.82)、(89.65±20.53)pg/mL,两组比较差异有统计学意义(P<0.05)。观察组的总有效率高于对照组(96.00%vs.78.00%),不良反应发生率低于对照组(8.00%vs.24.00%),两组比较差异有统计学意义(P<0.05)。结论埃索美拉唑三联疗法治疗十二指肠溃疡的疗效显著,能够降低患者体内血清TNF-α及HMGB1的表达,值得在临床上应用推广。
Objective To investigate the effect of esomeprazole triple therapy on the expression of serum TNF-α and HMGB1 in patients with duodenal ulcer. Methods Totally 100 cases of duodenal ulcer in our hospital from July 2014 to July 2015 were divided into observation group and control group randomly. Observation group was treated with esomeprazole triple therapy, and control group received omeprazole triple therapy. The changes of serum TNF-α ,HMGB1 ,BAO and gastrin levels before and after treatment in the two groups were compared, and the clinical efficacy and adverse reactions of the two groups were recorded. Results After treatment, the levels of TNF-α, HMGB1 ,BAO and gastrin in observation group were lower than those of control group,there being significant differ- ences （ P 〈 0.05 ）. The total effective rate in treatment group was higher than that of control group （ 96. 00% vs. 78.00% ,P 〈 0. 05 ） and incidence of adverse reaction was lower in treatment group （ 8.00% vs. 24. 00% , P 〈 0. 05 ）. Conclusion Among patients with duodenal ulcer, the use of esomeprazole triple therapy can result in a signifi- cant reduction in serum TNF-α and HMGBI expression and has good efficacy. It is worthy of clinical promotion.
出处
《实用药物与临床》
CAS
2016年第7期886-889,共4页
Practical Pharmacy and Clinical Remedies
